How to buy Biomarin Pharmaceutical stock (BMRN)

Biomarin Pharmaceutical is a biotechnology business based in the US. Biomarin Pharmaceutical shares (BMRN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $65.66 – a decrease of 0.53% over the previous week. Biomarin Pharmaceutical employs 3,401 staff and has a trailing 12-month revenue of around $2.8 billion.

Our top picks for where to buy Biomarin Pharmaceutical stock

Buy Biomarin Pharmaceutical stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biomarin Pharmaceutical stock price (NASDAQ: BMRN)

Use our graph to track the performance of BMRN stocks over time.

Biomarin Pharmaceutical shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$65.66
52-week range	$61.15 - $99.25
50-day moving average more info button	$66.94
200-day moving average more info button	$79.15
Wall St. target price	$97.35
PE ratio more info button	38.9699
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.66

Is it a good time to buy Biomarin Pharmaceutical stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biomarin Pharmaceutical price performance over time

Historical closes compared with the close of $65.66 from 2024-12-20

1 week (2024-12-13)	-0.53%
1 month (2024-11-22)	2.18%
3 months (2024-09-20)	-7.12%
6 months (2024-06-21)	-21.63%

1 year (2023-12-22)	-31.75%
2 years (2022-12-22)	-37.86%
3 years (2021-12-22)	89.95
5 years (2019-12-20)	84.75

Is Biomarin Pharmaceutical stock undervalued or overvalued?

Valuing Biomarin Pharmaceutical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biomarin Pharmaceutical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biomarin Pharmaceutical's P/E ratio

Biomarin Pharmaceutical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 39x. In other words, Biomarin Pharmaceutical shares trade at around 39x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Biomarin Pharmaceutical's PEG ratio

Biomarin Pharmaceutical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.4046. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biomarin Pharmaceutical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Biomarin Pharmaceutical's EBITDA

Biomarin Pharmaceutical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $426.1 million.

The EBITDA is a measure of a Biomarin Pharmaceutical's overall financial performance and is widely used to measure a its profitability.

Biomarin Pharmaceutical financials

Revenue TTM	$2.8 billion
Operating margin TTM	15.27%
Gross profit TTM	$1.6 billion
Return on assets TTM	3%
Return on equity TTM	6.25%
Profit margin	11.71%
Book value	$28.41
Market Capitalization more info button	$12.3 billion

TTM: trailing 12 months

Biomarin Pharmaceutical share dividends

We're not expecting Biomarin Pharmaceutical to pay a dividend over the next 12 months.

Biomarin Pharmaceutical share price volatility

Over the last 12 months, Biomarin Pharmaceutical's shares have ranged in value from as little as $61.15 up to $99.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biomarin Pharmaceutical's is 0.31. This would suggest that Biomarin Pharmaceutical's shares are less volatile than average (for this exchange).

Biomarin Pharmaceutical overview

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U. S.

Frequently asked questions

null
What percentage of Biomarin Pharmaceutical is owned by insiders or institutions?
Currently 0.874% of Biomarin Pharmaceutical shares are held by insiders and 97.788% by institutions. How many people work for Biomarin Pharmaceutical?
Latest data suggests 3,401 work at Biomarin Pharmaceutical. When does the fiscal year end for Biomarin Pharmaceutical?
Biomarin Pharmaceutical's fiscal year ends in December. Where is Biomarin Pharmaceutical based?
Biomarin Pharmaceutical's address is: 770 Lindaro Street, San Rafael, CA, United States, 94901 What is Biomarin Pharmaceutical's ISIN number?
Biomarin Pharmaceutical's international securities identification number is: US09061G1013 What is Biomarin Pharmaceutical's CUSIP number?
Biomarin Pharmaceutical's Committee on Uniform Securities Identification Procedures number is: 09061G101